{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:45:37Z","timestamp":1760982337329},"reference-count":39,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2007,10,10]],"date-time":"2007-10-10T00:00:00Z","timestamp":1191974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Active immunotherapies are one approach being developed as novel treatments for prostate cancer. Critical to the success of these therapies is the identification of appropriate target antigens. We have been seeking to identify immunologically recognized proteins, cancer\u2010testis antigens (CTA) in particular, in patients with prostate cancer that would be rational target antigens.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Using a previously reported panel of 29 different CTA, we used sera from 98 patients with prostate cancer and 50 healthy male blood donor controls to detect CTA\u2010specific IgG. We then further evaluated the expression of one antigen, SSX\u20102, in prostate cancer cell lines and tissues.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>We identified IgG specific for NY\u2010ESO\u20101, LAGE\u20101, NFX\u20102, and SSX\u20102 in at least 1\/98 individuals with prostate cancer. We demonstrated that SSX\u20102 is a prostate CTA, and its expression is associated with metastatic prostate cancer. In addition, we report that the treatment of at least two human prostate cancer cell lines with the DNA methylation inhibitor 5\u2010aza\u20102\u2032\u2010deoxycytidine induced the expression of SSX\u20102. In contrast, treatment of a normal prostate epithelial cell line (RWPE\u20101) with 5\u2010aza\u20102\u2032\u2010deoxycytidine did not induce SSX\u20102 expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Our findings suggest that SSX\u20102 could be further pursued as an immunotherapeutic target in prostate cancer, and that treatment with 5\u2010aza\u20102\u2032\u2010deoxycytidine could be exploited to modulate antigen expression in combination with immunotherapeutic approaches. Prostate 67: 1781\u20131790, 2007. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.20665","type":"journal-article","created":{"date-parts":[[2007,10,10]],"date-time":"2007-10-10T17:17:51Z","timestamp":1192036671000},"page":"1781-1790","source":"Crossref","is-referenced-by-count":41,"title":["Inducible expression of a prostate cancer\u2010testis antigen, SSX\u20102, following treatment with a DNA methylation inhibitor"],"prefix":"10.1002","volume":"67","author":[{"given":"Jason A.","family":"Dubovsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas G.","family":"McNeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,10,10]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0b013e3280eb10eb"},{"key":"e_1_2_1_4_2","first-page":"465","article-title":"Immunotherapy of prostate cancer","volume":"5","author":"Kipp R","year":"2007","journal-title":"Clin Adv Hem Onc"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2006.12.006"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5252"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2937"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.uct.2006.05.011"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67114-5"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.1066"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19980701)36:2<129::AID-PROS8>3.0.CO;2-D"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.4.293"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(199601)28:1<65::AID-PROS9>3.0.CO;2-N"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11810"},{"key":"e_1_2_1_15_2","first-page":"1","article-title":"The cancer\/testis genes: Review, standardization, and commentary","volume":"4","author":"Scanlan MJ","year":"2004","journal-title":"Cancer Immun"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0272.1989.tb02401.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.5.1914"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120001150"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1669"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1997.5052"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980610)76:6<903::AID-IJC22>3.0.CO;2-1"},{"key":"e_1_2_1_22_2","first-page":"2690","article-title":"5\u2010aza\u20102\u2032\u2010deoxycytidine\u2010induced expression of functional cancer testis antigens in human renal cell carcinoma: Immunotherapeutic implications","volume":"8","author":"Coral S","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0858"},{"key":"e_1_2_1_24_2","first-page":"10","article-title":"NY\u2010ESO\u20101 mRNA expression and immunogenicity in advanced prostate cancer","volume":"3","author":"Nakada T","year":"2003","journal-title":"Cancer Immun"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-003-0458-8"},{"key":"e_1_2_1_26_2","first-page":"1","article-title":"Humoral immune responses to testis antigens in sera from patients with prostate cancer","volume":"6","author":"Hoeppner LH","year":"2006","journal-title":"Cancer Immun"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3180de4d19"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.9.e45"},{"key":"e_1_2_1_31_2","first-page":"4766","article-title":"The SSX\u20102 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM\u2010MEL\u201040","volume":"56","author":"Tureci O","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000175685.36239.e5"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1203"},{"key":"e_1_2_1_34_2","first-page":"18","article-title":"Identification of an HLA\u2010A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM\u2010MEL\u201040\/S SX2","volume":"3","author":"Wagner C","year":"2003","journal-title":"Cancer Immun"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3020"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2006.100"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2020"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2381"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.11.4727-4741.2005"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.07112"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.20665","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.20665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:16:31Z","timestamp":1700064991000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.20665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,10]]},"references-count":39,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1002\/pros.20665"],"URL":"https:\/\/doi.org\/10.1002\/pros.20665","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,10]]}}}